Premium
Platelet‐activating factor (Paf) antagonist, WEB 2086, protects against Paf‐induced hypotension in Macaca fascicularis
Author(s) -
Stanton A.W.B.,
Izumi T.,
Antoniw J.W.,
Piper Priscilla J.
Publication year - 1989
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1989.tb11999.x
Subject(s) - platelet activating factor , antagonist , medicine , histamine , blood pressure , pulmonary artery , anesthesia , pathophysiology , pharmacology , cardiology , receptor
1 The actions of intravenously administered platelet‐activating factor (Paf) (0.1–3.33 nmol kg −1 ) and the effect of a recently described Paf antagonist, WEB 2086, were investigated in the anaesthetized open‐chest monkey, Macaca fascicularis . 2 Paf dose‐dependently reduced blood pressure, left ventricular pressure (LVP) and its first differential LV dP/dt . 3 Mean pulmonary artery pressure, recorded in three animals, was essentially unchanged by any dose of Paf. 4 WEB 2086 (0.22 μmol kg −1 , i.v.) attenuated the Paf‐induced changes in BP, LVP and LV dP/dt . The dose‐response curve for fall in BP was shifted to the right by one order of magnitude. 5 Histamine‐induced cardiovascular changes (systemic hypotension and tachycardia) were not affected by prior administration of WEB 2086. 6 WEB 2086 should be of value in assessing the role of Paf in pathophysiological conditions.